Conkwest is an innovative life sciences company that is developing and commercializing a robust product pipeline for the treatment of cancers and viral infections. Our products are based on the proprietary cancer-killing cell line NK-92 – the only cell line that can be commercialized as a direct, scalable, off-the-shelf cancer-killing product. NK-92, an unparalleled line of natural killer cells, directly attacks and kills abnormal cells on contact. Unlike other immunotherapies, NK-92 does not require an intact immune system to effect killing of diseased cells in the body. It has demonstrated broad anti-cancer activity both in-vitro and in clinical trials while sparing patients from debilitating adverse reactions commonly seen with traditional chemotherapies. Phase I trials have been completed at RUSH University and Frankfurt AM Main and preparations for a US phase II trial in lung cancer are currently underway. Conkwest has entered into licensing agreements with both public and private biotechnology companies, with many more anticipated, for the use of our products in the development and manufacture of monoclonal antibody therapeutic agents. Read more about Conkwest >>
Conkwest opens new research & development laboratory at Johnson & Johnson Innovation’s funded LabCentral in Kendal Square Cambridge, MA.
Conkwest’s portfolio of products includes the original NK-92 cell-line, currently in clinical trials, and several genetically enhanced lines. These modifications impart additional cancer killing features, each geared towards specific cancer applications. Our leading anti-cancer cell line is currently being evaluated in patients with leukemia and lymphoma.┬á Read about our portfolio of products >>
Top tier companies, including Abbott Biotherapeutics, Amgen, Bayer, BMS, MedImmune and Roche currently license our platform for their antibody research and development applications. The platform is also ideally suited for commercial release testing of clinical antibody products. Read about our ADCC assay tools >>